On September 9, 2022 Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, reported that its Chief Executive Officer, Michael Engsig, and Chief Business Officer & Cofounder, Agnete Fredriksen, will present at the H.C. Wainwright 24th Annual Global Investment Conference on Tuesday, September 13, 2022 at 11:00 a.m. ET / 5:00 p.m. CET and are available for 1:1 investor meetings (Press release, Nykode Therapeutics, SEP 9, 2022, View Source [SID1234619428]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live and archived webcast of the presentation can be accessed in the Investors section of the Company’s website here.